Home > Insider Trading > Filing (0000899243-20-035198)

Filing Details

Accession Number:: 0000899243-20-035198
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-28 16:30:26
Reporting Period:: 2020-12-22

Accepted Time:: 2020-12-28 16:30:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1402479	Medavail Holdings Inc.	MDVL	Pharmaceutical Preparations (2834)	900772394

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1668029	Fan Yu	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No
1766516	L.p. Management Medalpha Bridge Ally	430 Park Avenue, 12Th Floor, New York NY 10022	No	No	Yes	No
1808684	Ally Bridge Group-Wtt Global Life Science Capital Partners, L.p.	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No
1822947	Ally Bridge Group (Ny) Llc	430 Park Avenue, 12Th Floor, New York NY 10022	No	No	Yes	No
1831963	L.p. Fund Master Medalpha Bridge Ally	430 Park Avenue, 12Th Floor, New York NY 10022	No	No	Yes	No
1832106	Ltd. Management Abg	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No
1832107	Ally Bridge Medalpha Management Gp, Llc	430 Park Avenue, 12Th Floor, New York NY 10022	No	No	Yes	No
1832108	Ltd Gp Partners Capital Science Life Global Abg-Wtt	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No
1832109	Abg-Wtt Global Life Science Capital Partners Gp, L.p.	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No
1832110	Ltd Wtt-Medavail Abg	Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-22	9,287	$13.70	3,858,298	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-12-22	7,661	$13.70	2,897,966	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-12-23	11,890	$13.99	3,870,188	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-12-23	9,810	$13.99	2,907,776	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-12-24	4,871	$13.99	3,875,059	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-12-24	4,019	$13.99	2,911,795	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.